Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

Inclusion Criteria

• •Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer
• •Recurrent disease after platinum-based chemotherapy
• •* Must have experienced disease persistence during primary platinum-based therapy or recurrence within 12 months after completion of platinum-based chemotherapy ("platinum-refractory" or "platinum-resistant" disease)
• •* A patient receiving a second course of platinum-based chemotherapy for platinum-sensitive disease who then develops persistence or recurrence within 12 months is considered eligible for this trial
• •Must have measurable disease by RECIST criteria (phase II) (phase II closed as of 1/7/2011)
• •Must have received ≥ 1 prior platinum-based cytotoxic chemotherapy regimen (for primary disease) containing carboplatin, cisplatin, or other organoplatinum compound
• •* Initial treatment may have included any of the following:
• •* High-dose therapy
• •* Consolidation therapy
• •* Intraperitoneal (IP) therapy
• •* Extended therapy administered after surgical or nonsurgical assessment
• •* One additional non-cytotoxic regimen (e.g., monoclonal antibodies, cytokines, or small-molecule inhibitors) for recurrent or persistent disease allowed
• •Patients may have received hormonal therapy for management of disease (e.g., SERMs, aromatase inhibitors, progestins, and GnRH agonists)
• •No loculated ascites for which IP distribution of virus is not expected to be feasible
• •No known brain metastases
• •GOG performance status (PS) 0-2 (Karnofsky PS 60-100%)
• •Life expectancy \> 12 weeks
• •Leukocytes ≥ 3,000/mcL
• •Absolute neutrophil count ≥ 1,500/mcL
• •Hemoglobin ≥ 10 g/dL
• •Platelets ≥ 100,000/mcL
• •Total bilirubin normal
• •AST/ALT ≤ 2.5 times upper limit of normal
• •Creatinine normal
• •Ejection fraction \> 50% by echocardiogram or MUGA
• •Cardiac enzymes normal
• •Not pregnant or nursing
• •Fertile patients must use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation
• •Must be able to avoid direct contact with pregnant or nursing women, infants, or immunocompromised individuals while on study and for ≥ 3 weeks following the last dose of study agent administration
• •Cardiac conduction abnormalities (e.g., bundle branch block, heart block) are allowed if their cardiac status has been stable for 6 months before study entry
• •At least 4 weeks since most recent cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin C)
• •Recovered from adverse events due to agents administered more than 4 weeks earlier
• •No prior radiotherapy to the abdomen or pelvis
• •No other concurrent investigational agents
• •No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's malignancy